Lee's Pharmaceutical Holdings (HKSE:00950) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00950 Lee's Pharmaceutical Holdings Ltd HKSE:00950
73 GF Score
Price HK$1.09
GF Value HK$1.69
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lee's Pharmaceutical Holdings Valuation Rank Related Terms

HKSE:00950
73GF Score
Lee's Pharmaceutical Holdings Ltd HKSE:00950
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lee's Pharmaceutical Holdings (HKSE:00950) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$1.09 is trading 35.8% below its estimated GF Value™ of HK$1.69. GuruFocus considers Lee's Pharmaceutical Holdings to be Significantly Undervalued.

Key valuation signals for HKSE:00950:

  • Valuation Rank:
  • GF Value™: HK$1.69 vs. price of HK$1.09 (35.8% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the HKSE:00950 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
73GF Score

Get the complete analysis for HKSE:00950

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.09
Price
HK$1.69
GF Value